Senator James Lankford (R-OK) sent a letter to the President and CEO of CVS Health Karen Lynch and Executive Vice President of CVS Health and President of CVS Caremark David Joyner to question CVS’ move to prefer their own biosimilar instead of allowing customers to also access other low-cost biosimilars on the market.
top of page
bottom of page
コメント